Genolution

Genolution Change in Working Capital

The Change in Working Capital of Genolution (225220.KQ) as of Oct 22, 2026 is -1.84 B KRW. In the previous year, Change in Working Capital was 2.01 B KRW — a change of -191.65% (lower).

Change in Working Capital

-1.84 BKRW

YoY

-191.65%

Last updated:

Change in Working Capital of Genolution is 2025 -1.84 B KRW. Change in Working Capital of Genolution was 2024 2.01 B KRW. It decreases by -191.65% lower compared to the previous year.

The Genolution Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
-403.56 M KRW
Jan 1, 2019
-634.40 M KRW
Jan 1, 2020
-10.24 B KRW
Jan 1, 2021
-16.89 B KRW
Jan 1, 2022
-4.43 B KRW
Jan 1, 2023
2.39 B KRW
Jan 1, 2024
2.01 B KRW
Jan 1, 2025
-1.84 B KRW
The Genolution Change in Working Capital history
YEARChange in Working CapitalYoY
-1.84 BKRW-191.65%
2.01 BKRW-15.85%
2.39 BKRW-153.85%
-4.43 BKRW-73.75%
-16.89 BKRW+64.86%
-10.24 BKRW+1,514.90%
-634.40 MKRW+57.20%
-403.56 MKRW+869.64%
-41.62 MKRW-88.00%
-346.95 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Change in Working Capital of Genolution is -1.84 B KRW in 2025.

Change in Working Capital of Genolution changed from 2.01 B KRW to -1.84 B KRW, representing a -191.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Genolution since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genolution

All Key Metrics — Genolution